UNSPSC 51112502: Atrimustine

This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C41H47Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XC0K09B7K4, chemically known as estradiol 3-benzoate 17-glycolate, 4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate but more generally known as atrimustine, which bears US NIH Compound Identifier 53181. European Medicines Agency schedules Atrimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05605MIG.

UNSPSC 51112502 Atrimustine, a Commodity code, covers pharmaceutical procurement activity in state and local government health programs, though the recent opportunity record shows minimal direct activity under this specific drug code. The Texas Health and Human Services Commission issued Request for Information HHS0017013 in early April 2026 to explore direct-to-manufacturer prescription programs through its Therapeutic Pharmacy Initiative, seeking vendor capabilities for establishing contracts outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI targets vendors with experience in direct contracting for self-insured employers and government health plans, negotiated net pricing models, and value-based outcomes arrangements. This exploration-stage procurement does not yet commit to specific product volumes, pricing, or award values; it functions as market research to inform future formal solicitation strategy. The RFI mechanism signals Texas HHS's intent to reshape pharmacy procurement pathways before issuing a formal RFP with binding financial and temporal terms.

The single documented opportunity originates from a state health agency (Texas HHS Commission) and reflects activity in Texas only. The April 2026 RFI response deadline has passed. The absence of additional recent state and local opportunities under this Commodity code suggests limited current procurement velocity in atrimustine specifically; broader pharmaceutical procurement at the state and local level typically flows through pharmacy benefit managers, group purchasing organizations, and existing contracts rather than through direct-to-manufacturer models. Firms pursuing this code should monitor for Texas HHS's anticipated follow-on RFP and track similar direct-contracting pharmacy initiatives in other state health agencies, as the TPI model may expand beyond Texas if pilot implementation succeeds.